Abstract
The use of mycophenolate mofetil (MMF) in children with Systemic Lupus Erythematosus (SLE) is increasing. However, the clinical benefit of its monitoring has been scarcely studied, and little is known about its pharmacokinetics (PK) in this context.
Highlights
The use of mycophenolate mofetil (MMF) in children with Systemic Lupus Erythematosus (SLE) is increasing
The clinical benefit of its monitoring has been scarcely studied, and little is known about its pharmacokinetics (PK) in this context
To describe mycophenolic acid (MPA) PK, and to explore the relationships between exposure indices to MPA and the clinical status in children with SL. This retrospective study included 36 children with SLE already treated with a maintenance immunosuppressive therapy including MMF
Summary
The use of mycophenolate mofetil (MMF) in children with Systemic Lupus Erythematosus (SLE) is increasing. PReS-FINAL-2175: Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring JB Woillard1, B Bader-Meunier2*, R Salomon2, B Ranchin3, S Decramer4, M Fischbach5, E Berard6, F Saint-Marcoux7
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
